Treatment of one prostate cancer cell line with Telmisartan, an angiotensin receptor blocker, induced apoptosis, which could be partially inhibited by pharmacological or genetic down-regulation of PPARβ/δ activity or expression [117]. This evidence concerns the gene PPARD and prostate carcinoma.